Le Lézard
Classified in: Health
Subjects: HEALTH, ECONOMIC NEWS/TRENDS/ANALYSIS

Lost Productivity Due to Substance Use Cost the Canadian Economy $22.4 billion: New Report


OTTAWA, March 29, 2023 (GLOBE NEWSWIRE) -- Substance use cost the Canadian economy $49.1 billion in 2020. That's a jump of more than $11 billion between 2007 and 2020 or nearly 12% in per-person costs.

The latest available data is part of the Canadian Use Costs and Harms [CSUCH] 2007-2020 report released today by the Canadian Centre on Substance Use and Addiction (CCSA) in partnership with the University of Victoria's Canadian Institute for Substance Use Research (CISUR).

Lost productivity alone cost $22.4 billion or $589 per person in 2020. This includes the value of work lost due to premature deaths and long- and short-term disability.

"The fact that lost productivity was the leading category of costs shows that substance use is not just a healthcare issue," says Dr. Adam Sherk, a scientist at CISUR and a researcher for the study. "Employers can support their employees by developing supportive substance use policies and investing in prevention, harm reduction and treatment programs."

The report analyses substance use costs by four key categories. In addition to lost productivity (45.6% of the total costs), healthcare costs accounted for $13.4 billion (27.4%). Criminal justice costs were $10 billion (20.3%), while other direct costs contributed $3.3 billion (6.7%). These figures illustrate how substance use issues can be found in many aspects of our everyday lives and that solutions are needed to address them.

Additional findings from the report include:

"There were nearly 74,000 deaths due to substance use in 2020, which was nearly 200 lives lost each day. Alcohol and tobacco account for over 85% of deaths alone," explained Emily Biggar, CCSA Research and Policy Analyst and a researcher on the project. "Our estimates show not only how substance use affects the healthcare and criminal justice systems but also the ability of people in Canada to work and contribute to the economy. Initiatives across the spectrum of prevention, harm reduction and treatment are needed to improve the health and productivity of people in Canada."

This is the third update in the Canadian Substance Use Costs and Harms project following releases in 2018 and 2020. CCSA and CISUR developed the CSUCH report to better understand the societal economic costs and harms associated with substance use in Canada. These regularly updated estimates can be used to prioritize relevant public policies, create initiatives to target the harms caused by substance use, identify information gaps, research needs and refinements to national data reporting systems; measure the impact of changing levels and patterns of substance use, and make changes to policy and societal responses to substance use.

More information, such as national, provincial and territorial breakdowns and an online data visualization tool, is available at www.csuch.ca.

Dr. Adam Sherk is a scientist with CISUR and a researcher with CCSA's WHO/Pan-American Health Organization Collaborating Centre for Alcohol and Public Health Policy. His research focuses on substance use epidemiology and alcohol policy research. He created the International Model of Alcohol Harms and Policy, an alcohol research platform used by countries worldwide to estimate alcohol-caused harms. He has created or consulted on national alcohol harms monitoring projects in Australia, Finland, Sweden, New Zealand and the United States as well as Canada.

Emily Biggar, MPH, is a research and policy analyst at CCSA. In addition to being a member of the CSUCH scientific working group, Biggar contributes to CCSA's research on substance use trends by leading the implementation of the Community Urinalysis and Self-Report Project, a project focused on better understanding the use of drugs from the unpredictable toxic drug supply.

CISUR (Canadian Institute for Substance Use Research), based at the University of Victoria, is a network of individuals and groups dedicated to the study of substance use and addiction in support of community-wide efforts to promote health and reduce harm. Their research is used to inform a broad range of projects, reports, publications and initiatives aimed at providing Canadians access to happier, healthier lives, whether they use substances or not. To learn more, visit https://www.uvic.ca/research/centres/cisur/

CCSA was created by an act of Parliament to provide national leadership to address substance use in Canada. A trusted counsel, CCSA provides guidance to decision makers by harnessing the power of research, curating knowledge and bringing together diverse perspectives. To learn more, visit www.ccsa.ca.

Media Availability

Dr. Sherk is available for telephone, Zoom and on-camera interviews. He resides in Victoria, B.C.

To book an interview with Dr. Sherk, contact Amanda Farrell-Low ([email protected] or 250-472-5445).
Ms. Biggar is available for telephone, Zoom and on-camera interviews. She resides in Ottawa, Ont.

To book an interview with Ms. Biggar, contact Lee Arbon ([email protected] or 613-266-5469).


Follow Us:
Web: ccsa.ca | Twitter: @CCSACanada | Facebook: @CCSA.CCDUS | LinkedIn: CCSA

 CCSA was created by Parliament to provide national leadership to address substance use in Canada. A trusted counsel, we provide national guidance to decision makers by harnessing the power of research, curating knowledge and bringing together diverse perspectives.

CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of the Government of Canada.



These press releases may also interest you

at 12:28
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDItm (mavorixafor), recently approved by the U.S....

at 12:20
Soleo Health, a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi. Soleo Health Jackson offers a broad range of specialty...

at 12:08
Prices have gone up?and stayed up?since the pandemic, but Eyemart Express has bucked this consumer pricing trend by keeping its prescription eyewear affordable. Since its founding in 1990, the national optical retailer has remained committed to...

at 12:05
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic...

at 12:05
Pharmaceutical Strategies Group ("PSG"), an EPIC company, released its annual Trends in Specialty Drug Benefits Report, co-sponsored by Genentech, a member of the Roche Group, detailing the complexities of specialty drug access and affordability. The...

at 12:05
DNB Markets ("DNB") and Back Bay Life Science Advisors ("Back Bay"), acting through the DNB//Back Bay Healthcare Partnership are pleased to announce the dates for our highly anticipated 9th annual Nordic-American Healthcare Conference (NAHC)....



News published on and distributed by: